Skip header and navigation

1 records – page 1 of 1.

Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.

https://arctichealth.org/en/permalink/ahliterature99564
Source
EuroIntervention. 2010 Apr;5(8):898-905
Publication Type
Article
Date
Apr-2010
Author
Jensen Lisette Okkels
Tilsted Hans Henrik
Thayssen Per
Kaltoft Anne
Maeng Michael
Lassen Jens Flensted
Hansen Knud Noerregaard
Madsen Morten
Ravkilde Jan
Johnsen Søren Paaske
Sørensen Henrik Toft
Thuesen Leif
Author Affiliation
Department of Cardiology, Odense University Hospital, Denmark. okkels@dadlnet.dk
Source
EuroIntervention. 2010 Apr;5(8):898-905
Date
Apr-2010
Language
English
Publication Type
Article
Keywords
Aged
Angioplasty, Transluminal, Percutaneous Coronary - adverse effects - instrumentation - mortality
Cardiovascular Agents - administration & dosage
Chi-Square Distribution
Coronary Artery Disease - mortality - therapy
Denmark - epidemiology
Drug-Eluting Stents
Female
Follow-Up Studies
Humans
Incidence
Kaplan-Meiers Estimate
Male
Metals
Middle Aged
Myocardial Infarction - etiology
Paclitaxel - administration & dosage
Platelet Aggregation Inhibitors - therapeutic use
Proportional Hazards Models
Prosthesis Design
Registries
Risk assessment
Risk factors
Sirolimus - administration & dosage
Stents
Thrombosis - etiology - mortality
Time Factors
Treatment Outcome
Abstract
AIMS: Stent thrombosis is a serious complication of percutaneous coronary intervention (PCI). We examined the incidence of stent thrombosis and other outcomes in patients treated with PCI and paclitaxeleluting stents (PES), sirolimus-eluting stents (SES) or bare-metal stents (BMS). METHODS AND RESULTS: All patients who underwent PES, SES or BMS implantation from January 2002 to June 2005 were identified in the population-based Western Denmark Heart Registry. All were followed for 36 months. Cox regression analysis was used to estimate relative risk (RR), controlling for covariates. A total of 12,374 patients were treated with stents: 1,298 with PES, 2,202 with SES and 8,847 with BMS. The three-year incidence of definite stent thrombosis was similar in the DES group (1.1%) and in the BMS group (0.7%) (adjusted relative risk [RR]: 1.24; 95% confidence interval [CI]: 0.85-1.81). Very late definite stent thrombosis occurred more frequently in DES-treated patients (adjusted RR: 2.89, 95% CI: 1.48- 5.65). The three-year mortality rate did not differ significantly between the two groups. Target lesion revascularisation (TLR) was lower in DES-treated patients than in BMS-treated patients (adjusted RR: 0.71, 95% CI: 0.63-0.81). CONCLUSIONS: An increased risk of very late definite stent thrombosis was observed in DES-treated patients compared with BMS-treated patients, but a similar mortality was detected. TLR continued to be lower among patients receiving DES.
PubMed ID
20542774 View in PubMed
Less detail